6533b820fe1ef96bd127922a
RESEARCH PRODUCT
Assessment of cerebral microbleeds by susceptibility-weighted imaging in Alzheimer's disease patients: A neuroimaging biomarker of the disease.
Gianvincenzo SparaciaFrancesco AgnelloBenedetta SparaciaFederico MidiriGiuseppe La TonaAlberto Iaiasubject
MalePathologymedicine.medical_specialtytau ProteinsDisease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineCerebrospinal fluidNeuroimagingAlzheimer DiseasemedicineHumansRadiology Nuclear Medicine and imagingAlzheimer's disease; Cerebral microbleeds; magnetic resonance imaging; susceptibility-weighted imaging; Radiology Nuclear Medicine and Imaging; Neurology (clinical)AgedCerebral HemorrhageAmyloid beta-Peptidesmedicine.diagnostic_testbusiness.industryCerebral microbleedBrainMagnetic resonance imagingGeneral MedicineAlzheimer's diseaseMagnetic Resonance Imagingsusceptibility-weighted imagingSusceptibility weighted imagingBiomarker (medicine)FemaleNeurology (clinical)business030217 neurology & neurosurgeryBiomarkersdescription
Purpose The objective of this study was to correlate the presence and distribution of cerebral microbleeds in Alzheimer’s disease patients with cerebrospinal fluid biomarkers (amyloid-beta and phosphorylated tau 181 protein levels) and cognitive decline by using susceptibility-weighted imaging magnetic resonance sequences at 1.5 T. Material and methods Fifty-four consecutive Alzheimer’s disease patients underwent brain magnetic resonance imaging at 1.5 T to assess the presence and distribution of cerebral microbleeds on susceptibility-weighted imaging images. The images were analyzed in consensus by two neuroradiologists, each with at least 10 years’ experience. Dementia severity was assessed with the Mini-Mental State Examination score. A multiple regression analysis was performed to assess the associations between the number and location of cerebral microbleed lesions with the age, sex, duration of the disease, cerebrospinal fluid amyloid-beta and phosphorylated tau 181 protein levels, and cognitive functions. Results A total of 296 microbleeds were observed in 54 patients; 38 patients (70.4%) had lobar distribution, 13 patients (24.1%) had non-lobar distribution, and the remaining three patients (5.6%) had mixed distribution, demonstrating that Alzheimer’s disease patients present mainly a lobar distribution of cerebral microbleeds. The age and the duration of the disease were correlated with the number of lobar cerebral microbleeds ( P < 0.001). Cerebrospinal fluid amyloid-beta, phosphorylated tau 181 protein levels, and cognitive decline were correlated with the number of lobar cerebral microbleeds in Alzheimer’s disease patients ( P < 0.001). Conclusion Lobar distribution of cerebral microbleeds is associated with Alzheimer’s disease and the number of lobar cerebral microbleeds directly correlates with cerebrospinal fluid amyloid-beta and phosphorylated tau 181 protein levels and with the cognitive decline of Alzheimer’s disease patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 | The neuroradiology journal |